

**Canadian
Blood
Services**

BLOOD
PLASMA
STEM CELLS
ORGANS
& TISSUES

DIAGNOSTIC SERVICES

MANITOBA

YEAR IN REVIEW

JANUARY – DECEMBER 2021

Diagnostic Services “Year in Review” statistics are based on a January to December calendar year. The calendar year provides better correlation with Health Canada birth statistics.

SENIOR STAFF AND CONTACT INFORMATION

Red Cell Serology Laboratory Medical Director: Charles Musuka, MD, FRCPC	204-789-1099 cmusuka@sharedhealthmb.ca
Platelet Immunology Laboratory Medical Director Akash Gupta, MD, FRCPC	204-789-1125 akash.gupta@blood.ca
Diagnostic Services Manager Dora Lopes-Carvalho, MLT	204-789-1128 dora.lopescarvalho@blood.ca
Technical Supervisor, Testing Lynne Meilleur, MLT	204-789-1149 lynne.meilleur@blood.ca
<u>Charge Technologists:</u>	
Red Cell Serology: Sherry Watt, MLT	204-789-1090 sherry.watt@blood.ca
Red Cell Serology: Henri Beaubien, MLT	204-789-1093 henri.beaubien@blood.ca
Platelet Immunology Laboratory Jacqueline Wong, MLT	204-789-1105 Jacqueline.wong@blood.ca
Perinatal Laboratory Phone # Fax #	204-789-1088 204-789-1006
Crossmatch / Accession Laboratory Phone # Fax #	204-789-1085 204-779-8593
Platelet Immunology Laboratory Phone # Fax #	204-789-1152 204-789-1186
Diagnostic Services Website	https://blood.ca/en/hospital-services

TABLE OF CONTENTS

SENIOR STAFF AND CONTACT INFORMATION	2
TABLE OF CONTENTS.....	3
FIGURES.....	4
TABLES.....	5
PERINATAL LABORATORY	6
A. Testing Performed.....	6
B. Testing Frequency.....	6
C. Specimens Tested	7
D. Antibodies Identified	8
CROSSMATCH / REFERENCE LABORATORY	13
A. Testing Performed.....	13
B. Specimens Tested.	14
C. Antibodies Identified	15
PLATELET IMMUNOLOGY LABORATORY	19
A. Testing Performed.....	19
B. Specimens Tested	19
RED CELL GENOTYPING	21
QUALITY INDICATORS	24
A. Turnaround Times.....	24
B. Rejected Specimens	26
DIAGNOSTIC SERVICES UPDATE 2021.....	30
Presentations / Abstracts / Publications Listing.....	31

FIGURES

Figure 1: Total Perinatal Specimens Tested	7
Figure 2: Total Number of Perinatal Antibodies	10
Figure 3: Frequency of Clinically Significant Antibodies	10
Figure 4: Total Crossmatch Specimens Tested	15
Figure 5: Total Number of Crossmatch Antibodies	16
Figure 6: Frequency of Clinically Significant Antibodies 2021	18
Figure 7: Total Platelet Immunology Donor Specimens Tested	20
Figure 8: Total Platelet Immunology Patient Specimens Tested	21
Figure 9: Rh D Testing Algorithm.....	22
Figure 10: Perinatal Rejection Reasons	27
Figure 11: Crossmatch Rejection Reasons 2021.....	28
Figure 12: Platelet Immunology Rejection Reasons 2021	29

TABLES

Table 1: Perinatal Specimens Tested	7
Table 2: Total Number of Perinatal Antibodies Detected	8
Table 3: Perinatal Patient Antibody Titres 2021	11
Table 4: Perinatal Patient Combination Antibodies 2021	11
Table 5: Crossmatch/Reference Specimens Tested	14
Table 6: Total Number of Crossmatch Antibodies Detected	17
Table 7: Platelet Immunology Specimens Tested	20
Table 8: Patient # - RHD Type/Result 2021.....	23
Table 9: Turnaround Time – Routine Criteria by Specimen Type	24
Table 10: Turnaround Time – Routine Perinatal Specimens	24
Table 11: Turnaround Time – Routine Crossmatch Specimens	25
Table 12: Turnaround Time – Reference Specimens.....	25
Table 13: Turnaround Time - Platelet Immunology Specimens.....	25
Table 14: Quarterly Rejection Rates – Perinatal Specimens 2020.....	27
Table 15: Quarterly Rejection Rates – Crossmatch Specimens 2021.....	28
Table 16: Quarterly Rejection Rates – Platelet Immunology Specimens (Patient and Donor) 2021	29

PERINATAL LABORATORY

The Perinatal Laboratory within Diagnostic Services at Canadian Blood Services provides diagnostic testing of perinatal samples for blood type and red blood cell antibodies. Results from this screening assist physicians, midwives and nurse practitioners in ensuring the appropriate management of a pregnancy for both the patient and baby.

A. Testing Performed

Canadian Blood Services Perinatal Laboratory routinely performs the following tests:

- ABO/Rh blood type
- Screen for red blood cell antibodies
- Antibody Identification, if antibodies are detected
- Antibody Identification referrals
- Antibody Titration, if a clinically significant antibody is identified
- Phenotyping
- Fetal Bleed Screening Test
- Kleihauer-Betke Test for Quantitation of fetal-maternal hemorrhage
- Direct Antiglobulin Test for detection of HDFN (Hemolytic Disease of the Fetus/Newborn)
- Bedside testing during fetal cordocentesis

Automated ABO/Rh and Antibody Screen assays are routinely performed on the Immucor NEO Iris analyzer (hemagglutination and solid phase testing). A combination of solid phase testing and indirect antiglobulin tube testing using PEG for enhancement are the primary antibody identification methods.

B. Testing Frequency

Prenatal – Initial Testing: All patients should be tested upon their first prenatal visit.

Prenatal – 26-28 Weeks Gestation: All Rh-negative patients should be retested at 26-28 weeks gestation. Rh positive patients should also be retested at 26-28 weeks gestation when there is only one blood group result available (usually first pregnancy) or if patient is at increased risk of allo-immunization (e.g. previous transfusion, maternal trauma, obstetrical procedure or suspected fetal hemorrhage).

Prenatal– Antibody Present: If the antibody is known to cause HDFN, it is recommended that specimens be submitted every two to four weeks for the duration of the pregnancy dependant on the specificity of the antibody and the strength of the antibody titre. More frequent testing may be indicated if the antibody titre rises rapidly or if clinical monitoring mandates that additional sampling would provide helpful information. Less frequent sampling may also be recommended for antibodies that are unlikely to be clinically significant or in cases where clinical monitoring through fetal doppler ultrasound has commenced.

Postnatal: Following delivery, specimens from the patient and her baby should be tested if the Rh of the patient is unknown, the patient is Rh negative, the patient has a clinically significant antibody or if the baby shows signs of HDFN (i.e. anemia or jaundice). Midwives or hospitals that do not perform transfusion medicine testing should submit specimens to Canadian Blood Services. A fetal bleed screening test is performed if a Rh-negative patient delivers a Rh-positive baby. The Kleihauer-Betke assay is performed when the patient has a positive fetal bleed screening test.

Newborns (Cords): Cord blood or neonate specimens must be submitted with the postnatal specimen as noted above. ABO/Rh testing is performed on cord or neonatal, when indicated, on specimens submitted to Canadian Blood Services. The direct antiglobulin test is performed if the perinatal patient has a clinically significant antibody or on request if the baby shows signs of HDFN (i.e. anemia or jaundice). This is especially important when the perinatal patient is Rh negative or when the perinatal patient has a clinically significant antibody. If the baby has unexpected anemia or jaundice, assessment of the cord blood sample for blood group and DAT may also be helpful.

Partners: When a perinatal patient has an antibody capable of causing HDFN, specimens from the partner will be requested for ABO/Rh and antigen phenotyping. This will assist in assessing the probability of the baby being affected by the antibody. Partners' specimens may also be tested to assess Rh Immune Globulin (RhIG) eligibility of Rh negative perinatal patients.


C. Specimens Tested

The data includes all perinatal patient tested, including referral patients from other provincial jurisdictions. The total number of specimens tested shows a slight decrease when compared to the last 4 years as seen in *Table 1* below. The data in this report reflects a calendar year period to enable better correlation to other government statistical data (Statistics Canada birth statistics).

Table 1: Perinatal Specimens Tested

Specimen Type	Test Type	2017	2018	2019	2020	2021
Perinatal	Perinatal- Type and Screen	31,800	31,123	29,361	26,769	25,652
Partner	Partner- ABO/Rh	388	358	364	310	280
Cord- ABO/Rh	Cord- ABO/Rh	2,111	2,474	2,625	2,906	1,733
Total # of Specimens Tested		34,299	33,955	32,350	29,985	27,665
Total # of Patients Tested		24,248	24,079	23,360	24,793	22,393

Figure 1: Total Perinatal Specimens Tested



D. Antibodies Identified

In 2021, a total of 192 antibodies were reported (see *Table 2*). This is slightly less than 2020 where 212 antibodies were reported. One hundred and eighty patients had antibodies identified during their pregnancies (slightly decreased from 206 patients in 2020). Breakdown of antibodies identified within the 192 patients consisted of 183 clinically significant antibodies and 9 clinically insignificant antibodies. Twenty-four patients had multiple clinically significant antibodies. Passive anti-D data has been excluded from the preceding numbers.

Antibodies identified were considered clinically significant if they have been reported to cause HDFN. The most common clinically significant antibodies identified were anti-E, anti-K, anti-C, anti-M, and anti-D, (see *Figure 3*) which together represented 81.5% of the total antibodies identified.

Titres for 5 of the clinically significant antibodies increased from non-critical to critical levels during the pregnancy with a total of 20 antibody titres at critical levels (see *Table 3*). Recommendations were made for all patients with a critical titre level (current or previous pregnancy) and all Kell system antibodies to be referred to a High Risk Fetal Assessment Clinic for further follow-up and monitoring during pregnancy.

Table 2: Total Number of Perinatal Antibodies Detected

Perinatal Antibodies Identified 2021					
Clinically Significant Antibodies	2017	2018	2019	2020	2021
Anti-D	11	11	16	19	11
Anti-C	9	10	6	10	21
Anti-C ^w	2	0	0	0	0
Anti-Ce	0	0	0	1	1
Anti-ce	0	1	0	0	0
Anti-c	20	12	11	6	5
Anti-E	66	64	69	74	68
Anti-e	8	6	6	2	4
Anti-f	0	1	0	0	0
Anti-G	1	2	3	3	2
Anti-Ge3	0	1	0	0	1
Anti-K	56	58	51	43	36
Anti-Kp ^a	1	0	1	0	0
Anti-Kp ^b	1	0	0	0	0
Anti Lu ^a	1	0	0	0	0
Anti-Lu ^b	0	0	1	0	0
Anti-M*	18	16	14	18	13
Anti-S	6	7	6	6	7
Anti-s	2	0	1	1	0
Anti-Fy ^a	4	4	2	4	2
Anti-Fy ^b	4	4	1	2	0

Perinatal Antibodies Identified 2021					
Clinically Significant Antibodies	2017	2018	2019	2020	2021
Anti-Jk ^a	20	17	13	17	6
Anti-Jk ^b	4	4	1	4	4
Anti-Jk ³	1	0	0	0	0
Anti-Dj ^a	0	1	1	0	0
Anti-Dj ^b	0	1	1	0	0
Anti-Mj ^a	0	1	0	0	0
Anti-U	0	0	0	0	1
Anti-V	1	1	0	0	0
Anti-Wr ^a	2	1	2	2	1
Total	238	223	206	212	183

*Anti-M – IgG antibody detected

Clinically Insignificant Antibodies	2017	2018	2019	2020	2021
Anti-A ₁	1	0	0	0	0
Anti-He	1	0	0	0	0
Anti-JMH	1	1	1	0	1
Anti-Le ^a	11	17	13	8	7
Anti-Le ^b	2	2	1	0	0
Anti-N	2	1	1	0	0
Anti-P ₁	3	2	0	1	1
Passive Anti-D (not included in totals)	813	763	665	248	212
TOTAL: Clinically Insignificant Antibodies	21	23	16	9	9

Figure 2: Total Number of Perinatal Antibodies




Figure 3: Frequency of Clinically Significant Antibodies




Table 3: Perinatal Patient Antibody Titres 2021

Antibody	Critical Level	Non-Critical Level	Non-Critical to Critical
Anti-D	3	10	2
Anti-C	0	5	0
Anti-E	3	44	2
Anti-c	1	4	0
Anti-e	0	2	0
Anti-DC	0	1	0
Anti-Ec	1	4	1
Anti-Ce	0	1	0
Anti-CG	0	1	0
Anti-K*	2	3	0
Anti-Fya	0	2	0
Anti-Fyb	0	0	0
Anti-Jka	0	6	0
Anti-Jkb	0	1	0
Anti-M	0	9	0
Anti-S	0	4	0
Anti-s	0	0	0

***Note:** Anti-K is considered critical at any titre. Antibody titres for Kell system antibodies may be performed in Manitoba after consultation with the Medical Officer

Table 4: Perinatal Patient Combination Antibodies 2021

Combination Antibodies	Total
Anti-C, Anti-E	0
Anti-C, Anti-e	2
Anti-c, Anti-E, Anti-Jka	1
Anti-c, Anti-Jka	1
Anti-C, Anti-G	2
Anti-c, Anti-K	2
Anti-C, Anti-M	1
Anti-C, Anti-Jka	1
Anti-D, Anti-M	1
Anti-D, Anti-C, Anti-G	0
Anti-E, Anti-c	3
Anti-E, Anti-c, Anti-K, Anti-K, Anti-Fya	1
Anti-C, Anti-K, Anti-S	1
Anti-E, Anti-Fya	1
Anti-E, Anti-Jka	3
Anti-E, Anti-K	2

Combination Antibodies	Total
Anti-e, Anti-K	0
Anti-K, Anti-Jka	1
Anti-Fya, Anti-Jkb	1
Total	24

CROSSMATCH / REFERENCE LABORATORY

The Crossmatch/ Reference Laboratory Winnipeg Red Cell Serology, Diagnostic Services provides centralized transfusion medicine services and testing to approximately 70 hospitals in Manitoba and eastern Nunavut that do not perform these tests. Reference services are provided for 4 rural hospitals with crossmatching laboratories in Manitoba and 12 hospitals in Northwest Ontario. Hospital patients who are repeatedly transfused may develop red cell antibodies and as a result may have difficulty in tolerating transfusions. Diagnostic Services has specialized and experienced technologists that assist and provide consultation to hospital transfusion medicine laboratories (24 hours, 7 days per week). The Reference Laboratory identifies red cell antibodies and provides transfusion recommendations. Diagnostic Services has a varied selection of specialized procedures and rare reagents to resolve more difficult red cell antibody cases. Staff within our department may collaborate with other references laboratories such as the National Immunohematology Reference laboratory (NIRL).

Diagnostic Services Red Cell Antibody Investigations

In 2021, hospitals have referred 146 requests for red cell antibody identification.

Referring hospitals have different capabilities and expertise in resolving red cell antibody investigations.

Canadian Blood Services, Diagnostic Services provides consultation and testing support including antibody investigation, advanced or alternative techniques where required, and recommendations for compatibility testing methods and selection of appropriate donor unit phenotypes if necessary.

Reporting may include interim, final and supplemental reports, depending on the urgency of the testing, the need for patient transfusion and the complexity of investigation. When a new antibody is identified by the Diagnostic Services laboratory a patient wallet card may be provided.

A. Testing Performed

The Crossmatch/Reference Laboratory routinely performs the following tests:

- ABO/Rh blood type
- Screen for red blood cell antibodies
- Antibody Identification, if antibodies are detected
- Crossmatch, electronic and serological
- Isohemagglutinin Titre
- Phenotyping (patient and donor units)
- Transfusion Reaction Investigation
- Direct Antiglobulin Test
- Elution and Absorption
- Cold Agglutinin Screen
- Thermal Amplitude

Antibody Screening is routinely performed by solid phase testing. A combination of solid phase testing and indirect antiglobulin tube testing using PEG for enhancement are the primary antibody identification methods. PEG IAT is also the manual back-up method for antibody screening.

The Crossmatch Laboratory distributes both stock and crossmatched red cell and platelet components to those hospitals which receive all of their transfusion medicine services from Canadian Blood Services.

The Crossmatch Laboratory performs complex antibody investigations and distributes crossmatch compatible (or least incompatible) red cell units.

B. Specimens Tested.

The data in this report reflects a calendar year period to enable better correlation to other government statistical data (ie: Statistics Canada birth statistics).


The total number of crossmatch specimens tested has remained consistent over the last 4 years as illustrated in *Table 5* below. The implementation of the Trace Line laboratory information system (LIS) was completed at 16 hospitals in Winnipeg and rural Manitoba in 2015. These hospitals now hold a stock inventory of red blood cell components and perform electronic crossmatch on demand; thus, reducing the number of red blood cells issued and reserved for specific patients on hand in the hospital Blood Bank. The number of red blood cell components distributed has stabilized as hospitals appear to have adjusted inventories to optimal levels. As part of Choosing Wisely Canada, a “Just One” campaign that highlighted “Why give two when one will do?” was rolled out in late 2018 at the Winnipeg tertiary care facilities which may have contributed to the reduction in red blood cell utilization.

The spike in number of product transformation is a result of the implementation of Red Cell aliquots in January 2020. The lab will prepare and provide small volume red cell aliquots for neonatal and pediatric transfusion.

Table 5: Crossmatch/Reference Specimens Tested

Specimen Type	2017	2018	2019	2020	2021
Type and Screen	51,628	52,395	50,995	50,843	50,984
Antibody Investigations	3,801	3,232	3,575	4,048	3,303
Transfusion Reactions	167	162	136	124	121
Blood Components Distributed	40,125	36,986	37,292	35,783	36,057
Product Transformation	193	162	17	761	969
Diagnostic Titres	446	489	378	329	367
Test Totals (excluding components distributed)	56,235	56,440	55,101	56,105	55,744
Patients Tested	30,553	31,025	29,528	27,617	28,020

Figure 4: Total Crossmatch Specimens Tested



C. Antibodies Identified

In 2021, total of 1031 antibodies clinically significant and insignificant antibodies were reported (see *Table 6*). The distribution of the most common antibodies remains consistent. Six hundred and twenty-three patients had antibodies identified, of these; 197 patients had multiple antibodies.

The difference in number of antibodies detected since 2019 is a reflective of a process change in reporting made in the lab in February 2020 and may not represent a significant increase in the rate of antibodies being detected. This change in process did not affect the reporting of Perinatal antibodies, therefore the jump in number is not observed in that patient population. Antibodies will continue to be reported in this manner in Winnipeg for the foreseeable future and preliminary numbers suggest that 2021 will show consistency with what is reported in 2020.

Antibodies identified were considered clinically significant if they have been reported to cause acute or delayed hemolytic transfusion reactions. The most common clinically significant antibodies identified were: anti-E, anti-K, anti-D, anti-Jka, anti-c, anti-C, and anti-e, (see *Figure 5*).

Figure 5: Total Number of Crossmatch Antibodies





Table 6: Total Number of Crossmatch Antibodies Detected

Crossmatch Antibodies Identified 2021					
Clinically Significant Antibodies	2017	2018	2019	2020	2021
Anti-D	31	45	39	73	67
Anti-C	25	27	22	28	31
Anti-C ^w	4	2	2	3	7
Anti-c	17	19	23	18	12
Anti-E	101	88	78	180	219
Anti-e	7	7	17	18	28
Anti-f	0	0	0	1	1
Anti-G	0	0	0	0	0
Anti-K	92	79	87	156	142
Anti-M	5	7	5	12	12
Anti-N	0	1	0	0	0
Anti-S	6	4	5	10	11
Anti-s	0	1	0	1	1
Anti-Fy ^a	16	19	10	20	19
Anti-Fy ^b	5	3	0	7	6
Anti-Jk ^a	31	23	24	36	29
Anti-Jk ^b	5	7	11	11	10
Anti-Jk ³	0	1	0	0	0
Anti-Le ^a	8	3	12	14	14
Anti-Le ^b	0	3	1	0	2
Anti-Lu ^a	0	1	2	0	0
Anti-Lu ^b	0	0	0	0	0
Anti-Di ^a	2	0	1	0	1
Anti-Di ^b	1	1	1	0	0
Anti-Kp ^a	0	4	1	1	2
Anti-Kp ^b	1	0	0	0	2
Anti-P ₁	1	0	0	0	2
Anti-Wr ^a	0	0	4	1	0
Anti-A ₁	2	1	1	5	2
Anti-En ^a	0	0	0	0	0
Anti-V	3	0	0	1	0
Anti-Jsa	0	0	0	0	0
Anti-Mia	0	2	1	0	3
Anti-Yta	0	1	0	0	0
Anti-Ytb	1	0	0	0	0
Total	364	349	347	596	623

* The difference in number of antibodies noted since 2019 is a reflective of a process change in reporting and may not represent a significant increase in the rate of antibodies being detected.

Figure 6: Frequency of Clinically Significant Antibodies 2021



PLATELET IMMUNOLOGY LABORATORY

The Platelet Immunology Laboratory within Diagnostic Services at Canadian Blood Services provides human leukocyte (HLA) and platelet specific (HPA) antigen typing and antibody investigation testing to assist health care providers in the management of thrombocytopenic patients who have become refractory to vital platelet transfusions, patients affected by neonatal alloimmune thrombocytopenia and autoimmune disorders and patients suspected to have had platelet antibody mediated adverse transfusion events such as post transfusion purpura (PTP). The Laboratory also performs testing on patients and donors for the investigation of Transfusion Related Acute Lung Injury (TRALI). The Laboratory provides service to all Manitoba hospitals and is a national reference lab for any hospital in Canada requiring these testing services.

In addition, the Laboratory also performs HLA and HPA typing on blood donors prior to being placed onto a national platelet donor registry. The registry is used to conduct searches to identify suitably compatible donors who can be used for patients that show no benefit from conventional platelet components.

A. Testing Performed

The Platelet Immunology Laboratory routinely performs the following tests:

- HLA Antigen Typing
- HLA Antibody Screen
- HLA Antibody Identification, if antibodies are detected
- HLA Antigen Typing for disease association
- HPA Typing
- HPA Screening
- HPA Antibody Identification, if antibodies are detected
- Platelet Crossmatch
- Selection of HLA/HPA Compatible Donors for Platelet Transfusion

HLA antibody screening and identification is performed using Luminex bead technology. Whereas HPA antibody screening, identification and crossmatching are performed using a solid phase platform, commercial ELISA kits and the MAIPA method.

A combination of Luminex® multiplex technology, Bioarray eMAP® (Elongation-mediated Multiplexed Analysis of Polymorphisms) technology and/or MicroSSP are the primary HLA and HPA genotyping methods utilized for genotyping both patients and donors.

Selection lists of HLA/HPA compatible donors for patients' requiring platelet transfusion support are generated by the Platelet Immunology Lab using the national platelet donor database.

B. Specimens Tested

Table 7 below illustrates the total number of Platelet Immunology specimens tested.

Table 7: Platelet Immunology Tests Performed

Specimen Type		2017	2018	2019	2020	2021
Donor	HLA Antigen Typing	1,171	3,728	1,234	748	1,062
	HLA Antibody Screen/Identification	29	17	10	28	18
	HPA Antigen Typing	648	1918	615	337	534
	HPA Antibody Screen/Identification	79	9	31	11	16
Test Totals		1,927	5,672	1,890	1,124	1,630
Patient	HLA Antigen Typing	1,205	1,200	1,198	1,170	1,240
	HLA Antibody Screen/Identification	141	167	117	129	134
	HPA Antigen Typing	316	292	286	297	260
	HPA Antibody Screen/Identification	437	390	446	489	436
	Selection of HLA/HPA Selected Platelet Donors	395	333	289	486	425
Test Totals		2,494	2,382	2,336	2,571	2,495

Figure 7: Total Platelet Immunology Donor Specimens Tested





Figure 8: Total Platelet Immunology Patient Specimens Tested




RED CELL GENOTYPING

Canadian Blood Services is able to provide red cell antigen genotyping services through our National Immunohematology Reference Laboratory (NIRL) and Edmonton Diagnostic Services Laboratory. This service is used to aid in resolving complex immunohematology cases. Molecular testing combined with hemagglutination testing can provide better resolution to serological problems and guide patient transfusion requirements in some circumstances especially for sickle cell patients and patients with chronic transfusion requirements and multiple or complex antibodies.

Based on the following testing algorithm patients with serologically variable Rh D typing results may require genetic testing for the RHD gene.

Figure 9: Rh D Testing Algorithm



For 2021, the following results were obtained in patients using one of the two red cell antigen genotyping platforms available at CBS:

Table 8: Patient # - RHD Type/Result 2021

Patient	RHD Genotype	Predicted Phenotype	RHD Sequencing	Rh(D) Group
1	Weak D type 2	Weak D	RHD*01W.2	Positive
2	Weak D type 1	Weak D	RHD*01W.1	Positive
3	Normal RHD	D+	RHD*01/DIIIa-CE(4-7)-D	Positive
4	DAR		RHD*09.01	Negative
5	Weak D type 3	Weak D	RHD*01W.3	Positive
6	Normal RHD	D+	RHD*01	Positive
7	Normal RHD	D+	RHD*01	Positive
8	Weak D type 1	Weak D	RHD*01W.1	Positive
9	DAU4 DV type 5		RHD*10.04 RHD*05.05/DIIIa-CE(4-7)-D	Negative
10	Normal RHD DAU3	D+	RHD*01 RHD-10.03	Positive
11	Weak D type 3	Weak D	RHD*01W.3	Positive
12	RHD Deletion with DVII.1		RHD*01N.01 with RHD*07*01	Negative
13	Weak D type 3	Weak D	RHD*01W.3	Positive
14	Weak D type 2	Weak D	RHD*01W.2	Positive
15	Normal RHD	D+	RHD*01	Positive
16	Normal RHD	D+	RHD*01	Positive
17	Weak D type 3	Weak D	RHD*01W.3	Positive
18	DAR		RHD*09.01	Negative
19	Weak D type 1	Weak D	RHD*01W.1	Positive

QUALITY INDICATORS

The laboratories monitor many quality indicators and the two which are most relevant to this document are turnaround times and rejected specimens which are presented below.

A. Turnaround Times

To ensure timely reporting of patient test results, Canadian Blood Services monitors turnaround time (TAT) from when the specimen is received at Canadian Blood Services in Winnipeg to the time when the results are available. Since monitoring of this quality indicator began in 2008, the percentage of specimens has consistently exceeded the predefined TAT threshold. Samples whose testing exceeds the expected TAT are usually those where clinically significant antibodies are detected or where difficulty in finding compatible blood is encountered.

Table 9: Turnaround Time – Routine Criteria by Specimen Type

Specimen Type	Expected Turnaround Time	Expected % of Specimens Which Meet or Exceed Expected TAT
Routine Perinatal Specimens	72 hours	85%
Perinatal Specimens with Antibodies	72 hours	85%
Routine Crossmatch Specimens	24 hours	90%
Reference Specimens	72 hours	85%
Routine Platelet Immunology Specimens (NAIT, PTP, Platelet alloimmunization)	14 days	90%
HLA Disease Association Specimens	28 days	90%
HLA B*5701 Specimens	28 days	90%
Donor HLA/HPA Typing Specimens	60 days	90%

Table 10: Turnaround Time – Routine Perinatal Specimens

Turnaround Time (TAT)	2017	2018	2019	2020	2021
% of Specimens Tested within 72 hours	94%	95%	92%	87%	88%
% of Specimens Tested > 72 hours	6%	5%	8%	13%	12%

Table 11: Turnaround Time – Routine Crossmatch Specimens

Turnaround Time (TAT)	2017	2018	2019	2020	2021
% of Specimens Tested within 24 hours	100%	99%	99%	99%	99%
% of Specimens Tested > 24 hours	0%	1%	1%	1%	1%

Table 12: Turnaround Time – Reference Specimens

Turnaround Time (TAT)	2017	2018	2019	2020	2021
% of Specimens Tested within 72 hours	99%	99%	97%	100%	99%
% of Specimens Tested > 72 hours	1%	1%	3%	0%	1%

Table 13: Turnaround Time - Platelet Immunology Specimens

Turnaround Time (TAT)	2017	2018	2019	2020	2021
% of Specimens Tested within 14 days	85.3%*	97%	99%	98%	98%
% of Specimens Tested within 28 days	95.30%	94%	98%	98%	99%
% of Specimens Tested within 60 days	91%	99%	92%	100%	100%

* Preliminary results reported within 1-2 days of sample receipt.

B. Rejected Specimens

Each time a specimen is rejected, a reason for rejection is entered into our laboratory information system (LIS). This data is then retrieved and analyzed on a quarterly basis.

As described in **Table 14 and Figure 14**, the reasons for rejecting specimens in the Perinatal Laboratory are primarily problems with specimen labelling, requisitions and discrepancies between the requisition and the specimen. Average rejection rates have decreased from a high of 4.4% in 2012 to 3.4% in 2021 which correlates with increased efforts to contact customers and educate them on acceptable labelling criteria.

Table 15 and Figure 15 describe the reasons for rejecting specimens in the Crossmatch Laboratory; the majority of which involve problems with specimens. Problems with specimen labelling and discrepancies between the requisition and the specimen tube label constitute the main reasons for specimen rejection. Missing or incorrect information on the label and discrepancies in the name, personal health number (PHN) or date of collection continue to be the most common specimen labelling errors seen. Specimens are also rejected if the sample is a duplicate. The rejection rate for crossmatch specimens continued to remain low throughout 2021. The average rejection rates have decreased from a high of 2.9% in 2012 to 1.8% in 2021.

The rejection rates for perinatal specimens are higher than for crossmatch (pre-transfusion) specimens. The collection process for crossmatch specimens is controlled with stringent best practices and standards that must be followed. Crossmatch specimens are usually collected in hospitals and are sent to Canadian Blood Services via the hospital blood banks where the samples are pre-screened to determine if there are discrepancies between the sample and requisition. Perinatal specimens are most often collected in clinics and community collection sites where the identification and labelling process may be more variable. Although there may be differences in the collection process all specimens are scrutinized using the same stringent acceptance criteria prior to testing at Canadian Blood Services.

Some specimens for crossmatch have already been rejected by the referring hospital laboratory and total numbers of these rejected specimens are not included in our data.

Table 16 and Figure 16 describe the reasons for rejecting specimens in the Platelet Immunology Laboratory; the majority of which involve specimens. Samples may be rejected because of discrepancies between the specimen and the requisition, they are duplicate specimens that would not be tested; wrong tube type are all common reasons. The numbers represent an average rejection rate between both donor and patient rejections. Efforts to educate hospital customers continued throughout 2020 and 2021.

Table 14: Quarterly Rejection Rates – Perinatal Specimens 2021

Rejection Category	Q1	Q2	Q3	Q4
Requisition	77	46	39	49
Specimen	117	95	92	94
Discrepancies Between Requisition & Specimen	81	60	56	65
Discrepancies Between Current Requisition & Historical Records	28	16	36	20
Other	8	9	7	6
Total # specimens rejected	311	226	230	234
Total # specimens received	8,401	7,090	6,506	7,178
Rejections as a % of total	3.7%	3.2%	3.5%	3.3%

Figure 10: Perinatal Rejection Reasons




Table 15: Quarterly Rejection Rates – Crossmatch Specimens 2021

Rejection Category	Q1	Q2	Q3	Q4
Requisition	28	30	44	31
Specimen	87	109	109	96
Discrepancies Between Requisition & Specimen	71	85	110	92
Discrepancies Between Current Requisition & Historical Records	0	1	3	4
Other	10	12	9	10
Total # specimens rejected	196	237	275	233
Total # specimens received	8,858	8,665	8,897	25,576
Rejections as a % of total	2.2%	2.7%	3.1%	0.9%

Figure 11: Crossmatch Rejection Reasons 2021





Table 16: Quarterly Rejection Rates – Platelet Immunology Specimens (Patient and Donor) 2021

Rejection Category	Q1	Q2	Q3	Q4
Requisition	1	5	3	5
Specimen	24	30	29	46
Discrepancies Between Requisition & Specimen	3	3	7	5
Discrepancies Between Current Requisition & Historical Records	0	2	3	0
Unable to Enter Results in PROGESA	0	1	1	0
Other	0	3	1	0
Total # specimens rejected	45	44	44	59
Total # specimens received	571	614	564	645
Rejections as a % of total	7.9%	7.2%	7.8%	9.1%

Figure 12: Platelet Immunology Rejection Reasons 2021



DIAGNOSTIC SERVICES UPDATE 2021

Updates pertain to all Diagnostic Services sites within Canadian Blood Services: Vancouver, Edmonton, Winnipeg, and Brampton

ALL	<p>NEO Iris Analyzer implemented April to June 2021.</p> <p>Eight NEO Instruments in Diagnostic Services were replaced with the next generation NEO IRIS instrument. NEO Iris performs ABO/RH and antibody testing.</p> <ul style="list-style-type: none"> • Edmonton- 2 NEO Iris' implemented May 2021 • Vancouver- 2 NEO Iris' implemented April and May 2021 • Winnipeg- 3 NEO Iris' implemented May and June 2021, with a fourth to be installed at CBS St.B satellite site in 2022"
Edmonton	Edmonton DS obtained the CPSA 4-year accreditation on 2021-02-25.
Edmonton	Transfer of HEA and RHCE genotype testing to Brampton, 2021-10-01
Vancouver	Awarded CAP Accreditation Dec 2021.
Vancouver	CPSBC – DAP ISO 15189 Audit. ISO 15189 accreditation pending final acceptance.
Winnipeg	Preparation for implementation of the Canadian Blood Services satellite Lab at St Boniface Hospital in March 2022. The Lab will act as a contingency site for services delivered by Winnipeg Diagnostic Services.
Winnipeg	Implementation of equipment in NPIRL – Multisizer 3 (cell counter) and thermocyclers

Winnipeg	Management of supplies, inventory and testing to ensure provision of services are not impacted during supply chain issues experienced in a pandemic.
Winnipeg	eTraceLine environments (perinatal and Crossmatch) were merged to allow better efficiency and ease of use for the labs noe that staff are cross trained.
Winnipeg	Project to implement HistoTrac and replace the access database currently used as the LIS began in Winnipeg in 2021. Projected implementation is December 2022.
Presentations / Abstracts / Publications Listing	
<i>Lhevinne Ciurcovich, Lynnette Beaudin, Arianne Fuellos, Balkar Gill, Ilona Resz, Debra Lane, Judith Hannon, Gwen Clarke, Melanie Bodnar. Comparison of Manual SIAT vs Automated Solid Phase Methodology for Perinatal Antibody Titration. Poster, CSTM 2021</i>	
<i>Lhevinne Ciurcovich¹, Sarah Manfredi², Sarah Buchko², Darlene Mueller², Michelle Wong², Mohammad Bahmanyar², MatthewYan¹, Gwen Clarke¹. Anti-IgA Implicated in Hemolytic Disease of the Fetus and Newborn in an Indigenous Woman. Poster, CSTM 2021</i>	
1: Canadian Blood Services, BC and Yukon Centre	
2: Fraser Health Authority, British Columbia	
<i>Lhevinne Ciurcovich, Gwen Clarke, Matthew Yan. A Case of ABO Chimerism in a Perinatal Patient. Poster, CSTM 2021</i>	
<i>Lhevinne Ciurcovich. Cell-Free Fetal DNA Testing: Advantages, Challenges and Limitations. Presentation: Virtual Conference, 22nd Annual Education Day on Blood Transfusion Issues, 2021-09-24.</i>	

Lhevinne Ciurcovich. Immunohematology Case Studies. Presentation: Immucor ImmuTECH Education Day (Virtual) 2021-05-05.

Lynnette Beaudin, Dr. Lani Lieberman MD, FRCP, Fetal and neonatal alloimmune thrombocytopenia (FNAIT): Diagnosis, Investigation and Treatment.
Presentation: U of T Monthly Transfusion Rounds (Virtual) 2021-02-25

Bodnar M, Hannaford K, Montemayor-Garcia C, Hannon J. Blindspots in Immucor BioArray RHD Molecular BeadChip Test: A Review of Cases at Canadian Blood Services Referred Out for RHD Gene Sequencing. Poster/Abstract, CSTM 2021

Floch A, Vege S, Berardi P, Hannon J, Ochoa-Garay G, Lomas-Francis C, et al. A change in RHD is associated with aberrant transcription and very weak D phenotype. Transfusion 2021

Flegel WA, Bodnar M, Clarke G, Hannon J, Lieberman L., 'What constitutes the most cautious approach for a pregnant person with weak D type 4.0?'
Letter to the Editor, CMAJ June 2021